Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains?

Zacks10-02

Enanta Pharmaceuticals (ENTA) shares soared 5.6% in the last trading session to close at $10.94. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2472186525?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/gJgEkXPgfL3Ox7pCWacu5w--~B/aD02MzM7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0151e33b3a4185acc9249fc63a178ccd","is_english":true,"pubTime":"2024-10-02 19:53","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2472186525","market":"us","top_or_hot":-1,"title":"Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains?","media":"Zacks","content":"<div>\n<p>Enanta Pharmaceuticals (ENTA) shares soared 5.6% in the last trading session to close at $10.94. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...</p>\n\n<a href=\"https://finance.yahoo.com/news/enanta-pharmaceuticals-enta-surges-5-115300031.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEnanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-02 19:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/enanta-pharmaceuticals-enta-surges-5-115300031.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Enanta Pharmaceuticals (ENTA) shares soared 5.6% in the last trading session to close at $10.94. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...</p>\n\n<a href=\"https://finance.yahoo.com/news/enanta-pharmaceuticals-enta-surges-5-115300031.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4547","symbol_name":"WSB热门概念","start_time":0,"source_url":"https://finance.yahoo.com/news/enanta-pharmaceuticals-enta-surges-5-115300031.html","article_id":"2472186525","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/gJgEkXPgfL3Ox7pCWacu5w--~B/aD02MzM7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0151e33b3a4185acc9249fc63a178ccd"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2472186525","pubTimestamp":1727869980,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Enanta Pharmaceuticals  shares soared 5.6% in the last trading session to close at $10.94. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 19.6% loss over the past four weeks.Last week, the company announced positive top-line data from a phase IIa human challenge study evaluating its pipeline candidate, EDP-323, in healthy adults infected with respiratory syncytial virus. The study met primary and secondary endpoints by demonstrating that treatment with once-daily EDP-323 led to highly statistically significant reductions in both viral load and clinical symptoms versus placebo. This might have driven the share price rally.For Enanta Pharmaceuticals, the consensus EPS estimate for the quarter has been revised 5.3% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on ENTA going forward t","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4547":"WSB热门概念","ENTA":"Enanta Pharmaceuticals Inc.","BK4139":"生物科技","BCRX":"BioCryst制药"},"translate_title":"Enanta Pharmaceuticals(ENTA)飙升5.6%：这是进一步上涨的迹象吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ENTA":1,"BCRX":0.9},"content_text":"Enanta Pharmaceuticals (ENTA) shares soared 5.6% in the last trading session to close at $10.94. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 19.6% loss over the past four weeks.\nLast week, the company announced positive top-line data from a phase IIa human challenge study evaluating its pipeline candidate, EDP-323, in healthy adults infected with respiratory syncytial virus. The study met primary and secondary endpoints by demonstrating that treatment with once-daily EDP-323 led to highly statistically significant reductions in both viral load and clinical symptoms versus placebo. This might have driven the share price rally.\nThis biotechnology company is expected to post quarterly loss of $1.16 per share in its upcoming report, which represents a year-over-year change of +12.8%. Revenues are expected to be $18.73 million, down 1.1% from the year-ago quarter.\nEarnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.\nFor Enanta Pharmaceuticals, the consensus EPS estimate for the quarter has been revised 5.3% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on ENTA going forward to see if this recent jump can turn into more strength down the road.\nThe stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>\nEnanta Pharmaceuticals is a member of the Zacks Medical - Drugs industry. One other stock in the same industry, BioCryst Pharmaceuticals (BCRX), finished the last trading session 2.9% lower at $7.38. BCRX has returned -12.5% over the past month.\nFor BioCryst , the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.07. This represents a change of +63.2% from what the company reported a year ago. BioCryst currently has a Zacks Rank of #3 (Hold).\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nEnanta Pharmaceuticals, Inc. (ENTA) : Free Stock Analysis Report\nBioCryst Pharmaceuticals, Inc. (BCRX) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2472186525"}